Director of the Board
Tyge Korsgaard (Danish, born 1957) joined PILA PHARMA in 2019 as Director of the Board due to his significant experience with development of SME’s in the life science industry as an institutional investor.
Tyge Korsgaard holds an MSc (economics) from Aalborg University (1983) and has since then gained extensive experience in all disciplines of private equity and venture capital, including Initial Public Offerings (IPO’s).
Tyge served as VP at Dansk Erhvervsinvestering 1998-2007 and Senior Investment Manager at Maj Invest (2007-2013).
From 1998-2013, Tyge was responsible for life science investments in Dansk Erhvervsinvestering, one of the first life science investment funds in Denmark.
As an example of Tyges impressive track record as institutional investor, Dansk Erhvervsinvestering achieved a remarkable return (IRR: 18.3% p.a.) during the period when Tyge Korsgaard was part of its management (1988-2013). The portfolio consisted in that period of approx. 50% life science companies.
Previously, he has had board positions in more than 25 companies, including Genmab A/S (observer) and Zealand Pharma A/S (until they were quoted on the stock exchange) and Kelsen Group A/S, 2D Holding (3D Danish Diagnostic Development A/S), Ellipse A/S, Neurodan A/S and A/S Boligbeton until they were sold successfully.
Currently, Tyge Korsgaard is CEO of Tyge Korsgaard Consult ApS, providing consultancy related to Equity capital (M&A/Capital increase) and business development.
Besides, he is board member in Vivostat A/S (Chairman and co-owner since 2015), Familien Skak Holding ApS (Since 2017) and Fonden DSK Invest 1 GP (Den Sociale Kapitalfond, since 2017).